Allicin‒Decorated FeO_1-xOH Nanocatalytic Medicine for Fe²⁺/Fe³⁺ Cycling‒Promoted Efficient and Sustained Tumor Regression.

ABSTRACT: In the tumor treatment by Fenton reaction‒based nanocatalytic medicines, the gradual consumption of Fe(II) ions greatly reduces the production of hydroxyl radicals, one of the most active reactive oxygen species (ROS), leading to much deteriorated therapeutic efficacy. Meanwhile, the ROS consumption caused by the highly expressed reduced glutathione (GSH) in the tumor microenvironment further prevents tumor apoptosis. Therefore, using the highly expressed GSH in tumor tissue to promote the Fe(III) reduction to Fe(II) can not only weaken the resistance of tumor to ROS attack, but also generate enough Fe(II) to accelerate the Fenton reaction. In view of this, an allicin‒modified FeO_1-xOH nanocatalyst possessing varied valence states (II, III) has been designed and synthesized. The

SUBMITTER: Jie Z 

PROVIDER: S-EPMC11348051 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature